fda warning letter compounding semaglutide october 2025 alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products September 8, 2025: FDA launches
Description
Our 5 mg/2 mL dosage chart covers this concentration in even greater detail
However, follow-up schedules for patients on GLP-1 therapy are becoming more flexible
9 To avoid hypoglycemic events when dispensing exenatide in combination with an SU, it is important to reduce the SU dose on initiation of exenatide and when titrating the exenatide dose upward
Refer to the cited studies in the Research Studies section above for original source data
